Attributes | Values |
---|
rdf:type
| |
Description
| - Particle size distribution in both HDL and LDL is reflected in the fractional esterification rate of cholesterol by lecithin cholesterol acyltransferase (LCAT) in plasma depleted of apoB containing lipoproteins (FER(HDL)). We studied FER(HDL) in a group of patients with type 2 diabetes and determined the impact of two different PPAR agonists (fenofibrate and rosiglitazone) on this marker of lipoprotein particle quality. Both fenofibrate and rosiglitazone improve FER(HDL) in patients with type 2 diabetes. The effect is more pronounced for rosiglitazone. Qualitative change of plasma lipoproteins reflected by FER(HDL) can contribute to antiatherogenic action of PPAR agonists
- Particle size distribution in both HDL and LDL is reflected in the fractional esterification rate of cholesterol by lecithin cholesterol acyltransferase (LCAT) in plasma depleted of apoB containing lipoproteins (FER(HDL)). We studied FER(HDL) in a group of patients with type 2 diabetes and determined the impact of two different PPAR agonists (fenofibrate and rosiglitazone) on this marker of lipoprotein particle quality. Both fenofibrate and rosiglitazone improve FER(HDL) in patients with type 2 diabetes. The effect is more pronounced for rosiglitazone. Qualitative change of plasma lipoproteins reflected by FER(HDL) can contribute to antiatherogenic action of PPAR agonists (en)
|
Title
| - Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus
- Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus (en)
|
skos:prefLabel
| - Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus
- Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus (en)
|
skos:notation
| - RIV/67985823:_____/08:00338069!RIV10-MZ0-67985823
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - N, P(NR8328), Z(AV0Z50110509)
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/67985823:_____/08:00338069
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - fenofibrate; rosiglitazone; type 2 diabetes mellitus (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Neuroendocrinology Letters
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Dobiášová, Milada
- Fait, T.
- Vrablík, M.
- Češka, R.
- Štulc, T.
- Prázný, M.
- Doležalová, R.
- Kasalová, Z.
|
http://linked.open...ain/vavai/riv/wos
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |